

Alcidion Group Limited (ABN 77 143 142 410)

Appendix 4D

& Financial statements for the period ended 31 December 2022

Results for announcement to the market

Reporting Periods

Current reporting period	Half-year ended 31 December 2022
Previous reporting period	Half-year ended 31 December 2021

Key information

		% Change		\$000
Total revenue from ordinary activities	Up	48%	to	18,984
Loss from ordinary activities after tax attributable to members	Down	52%	to	(2,842)
Net loss for the period attributable to members	Down	52%	to	(2,842)

Details relating to dividends

No dividends were paid or proposed for the current or previous corresponding half-year period.

Explanation of results

The \$3,108K (52%) improvement in the loss from ordinary activities after tax is a result of:

- A \$6,123K (48%) increase in revenue versus the prior corresponding period (PCP) – driven by a combination of organic and acquisitive growth. Underlying organic revenue growth was 22%. Leading to a gross profit increase of \$5,425K (50%)
- A decrease of \$2,106K in costs related to acquisitions (current period: \$Nil), offset by an increase of \$3,318K in operating expenditure and a \$1,008K increase in depreciation & amortisation, related to acquired intangibles

Additional information supporting the Appendix 4D disclosure requirements can be found in the Directors' report and the consolidated financial statements for the half-year ended 31 December 2022 lodged with this document.

Net tangible assets per security

	31 December 2022	30 June 2022
Net tangible assets per security	(\$0.005)	(\$0.004)

This Appendix 4D is based on the attached half-year financial report which has been reviewed by the Group's auditors, William Buck. A copy of William Buck's review report is included in the attached half-year financial report.



Alcidion Group Limited

**Financial report for the half year
ended 31 December 2022**

CONTENTS

Directors' Report	1
Auditor's Independence Declaration	5
Consolidated Statement of Profit or Loss and Other Comprehensive Income	6
Consolidated Statement of Financial Position	7
Consolidated Statement of Changes in Equity	8
Consolidated Statement of Cash Flows	9
Notes to the Financial Statements	10
Directors' Declaration	15
Independent Auditor's Review Report	16
Corporate Directory	18

Directors' Report

The directors submit herewith the financial report of Alcidion Group Limited and its subsidiaries ("Alcidion", "the Group" or, the "Company") for the half-year ended 31 December 2022. In order to comply with the provisions of the *Corporations Act 2001*, the directors report as follows:

Directors

The following persons were directors of Alcidion Group Limited during the whole of the financial half-year and up to the date of this report, unless otherwise stated:

Ms Rebecca Wilson	Ms Kate Quirke
Mr Simon Chamberlain	Dr. Malcolm Pradhan (resigned 30 November 2022)
Ms Victoria Weekes	Mr Daniel Sharp

Principal activities

The principal activities of Alcidion include the development and licensing of its own healthcare software products (Miya Precision and its associated modules, including Miya Observations, Flow, Task Management and PAS), the reselling of selected healthcare software products from its strategic partners and the delivery of product implementation, product support and maintenance, systems integration and data analysis services to healthcare customers in Australia, New Zealand and the United Kingdom.

Review of operations

Operating results

For the half-year period ended 31 December 2022, Alcidion delivered:

- Revenue of \$18,984K a 48% increase on the prior corresponding period (PCP) revenue of \$12,861K
- Gross profit of \$16,337K (86%) a 50% increase on the PCP gross profit of \$10,912K (85%)
- A loss after income tax of \$2,842K a 52% improvement on the PCP loss of \$5,950K
- An EBITDA loss of \$1,198K, an improvement of \$4,213K over the EBITDA loss in the PCP of \$5,411K
- An Underlying EBITDA loss of \$1,066K, an improvement of \$2,085K over the underlying EBITDA loss in the PCP of \$3,151K

Reconciliation of Loss after tax to non-IFRS EBITDA & underlying EBITDA:

Half-year ended:	31 Dec 2022 \$000	31 Dec 2021 \$000
(Loss) after tax attributable to the owners of the company	(2,842)	(5,950)
<i>Add:</i>		
Depreciation & amortisation expense	1,542	534
Income tax expense	81	-
Finance costs	64	27
<i>Less:</i>		
Income tax expense benefit	-	9
Interest revenue	43	13
EBITDA (loss)	(1,198)	(5,411)
<i>Add back:</i>		
Costs related to acquisitions	-	2,106
Non-cash cost of performance rights	132	154
Underlying EBITDA (loss)	(1,066)	(3,151)

Financial Position

Summary of financial position:

	31 Dec 2022	30 June 2022
	\$000	\$000
Cash and cash equivalents	11,868	17,339
Net current assets	765	1,871
Net assets/equity	91,115	93,955
Net tangible assets	(6,732)	(4,863)

Equity

Summary of share capital:

	31 Dec 2022	30 June 2022
Issued capital (\$000)	110,511	110,511
No. of issued shares	1,268,069,053	1,268,069,053
No. performance rights	20,334,755	9,479,412
Share price (\$)	0.145	0.110
Market capitalisation (\$M)	183.9	139.5

Significant contract wins

During the half Alcidion contracted new sales with a total contract value (TCV) of \$18.6M - \$5.5M of which is able to be recognised in the current financial year provided milestones are achieved.

Notable contract wins during the period include:

University Hospital Southampton NHS Foundation Trust (UHS):

- Initial 3-year agreement to implement Miya Precision as the foundation for their Electronic Patient Record (EPR). Alcidion will partner with UHS to deliver a modular EPR using a combination of Alcidion and UHS incumbent products, with initial implementation including the Miya Access, Command, Emergency and Flow modules.
- Increases NHS penetration with at least one Alcidion product now in 40 NHS Trusts while further establishing the first customer in a new Integrated Care System (ICS), Hampshire and Isle of White.

Bolton NHS Foundation Trust (Bolton):

- Contract to implement Miya Flow, which will replace the ExtraMed solution currently being used. The agreement introduces Miya Flow to the Greater Manchester ICS and extends Alcidion's footprint at Royal Bolton Hospital, complementing the existing Miya Observations module.

University Hospitals Dorset NHS Foundation Trust (Dorset):

- Contract renewal agreement for use of the Silverlink Patient Care System (PCS) solution. The agreement extends the existing relationship for a further 3 years validating the long-standing relationships Alcidion holds with its customers.

Leidos Australia (ADF):

- Signed an extension to an existing contract with Leidos Australia for the delivery of a Health Knowledge Management system to support healthcare services across the Australian Defence Force (ADF). The contract extension includes the addition of the Miya Observations and Assessments modules as well as extended use of Miya Precision to additional settings within the ADF environment.
- Both contracts (initial contact plus this additional contract scope) have the option for renewal for up to 15 years.

Significant changes in state of affairs

Performance rights:

On 16 December 2022 the Company issued 11,522,401 performance rights to employees in accordance with the Alcidion Group Limited Equity Incentive Plan.

A further 667,058 Performance rights were forfeited and cancelled during the period.

Other than the above, no significant changes in the state of affairs of the Group occurred during the interim period.

Significant Events after the Balance Date

There were no significant events after 31 December 2022.

Likely Developments and Expected Results

The Group expects to maintain the present status and level of operations and hence there are no likely developments in the Group's operations.

Dividends

No dividends were paid or declared during the half year and no recommendation for payment of dividends has been made.

Rounding


The Company is a company of the kind referred to in *ASIC Corporations (Rounding in Financials/Directors' Reports) Instruments 2016/191*, dated 24 March 2016, and in accordance with that Corporations Instrument amounts in this directors' report are rounded off to the nearest thousand dollars, unless otherwise indicated.

Auditors Independence Declaration

A copy of the auditor's independence declaration as required under s.307C of the Corporations Act 2001 is set out on page 5.

Signed in accordance with a resolution of directors made pursuant to s.306(3) of the Corporations Act 2001.

On behalf of the Directors



Rebecca Wilson
Non-Executive Chair
Melbourne, 24 February 2023

**AUDITOR'S INDEPENDENCE DECLARATION UNDER SECTION 307C OF THE CORPORATIONS ACT
2001 TO THE DIRECTORS OF ALCIDION GROUP LIMITED**

I declare that, to the best of my knowledge and belief, during the half-year ended 31 December 2022 there have been:

- no contraventions of the auditor independence requirements as set out in the *Corporations Act 2001* in relation to the review; and
- no contraventions of any applicable code of professional conduct in relation to the review.



William Buck (SA)
ABN: 38 280 203 274



G.W. Martinella
Partner

Dated this 24th day of February, 2023.

Statement of profit or loss and other comprehensive income

CONSOLIDATED	Note	31 Dec 2022 \$000	31 Dec 2021 \$000
Revenue		18,984	12,861
Direct costs		(2,647)	(1,949)
Gross Profit		16,337	10,912
Interest income		43	13
Employee benefits expense		(14,606)	(11,917)
Professional fees		(540)	(721)
Marketing expenses		(407)	(296)
Costs related to acquisitions		-	(2,106)
Other expenses		(1,982)	(1,283)
Depreciation and amortisation expense		(1,542)	(534)
Finance costs		(64)	(27)
Loss before income tax expense		(2,761)	(5,959)
Income tax benefit / (expense)		(81)	9
Loss after tax attributable to the owners of the Company		(2,842)	(5,950)
Other comprehensive income/(loss) net of tax			
<i>Items that may be reclassified subsequently to profit or loss:</i>			
Exchange differences on translation of foreign operations		(130)	(292)
Total comprehensive loss for the half year attributable to the owners of the Company		(2,972)	(6,242)
(Loss) Per Share			
Basic and diluted loss per share (cents)	8	(0.22)	(0.56)

The notes following the financial statements form part of the financial report.

Statement of financial position

CONSOLIDATED	Note	31 Dec 2022 \$000	30 June 2022 \$000
Current assets			
Cash and cash equivalents		11,868	17,339
Trade and other receivables		5,625	7,251
Other assets		2,380	1,672
Total current assets		19,873	26,262
Non-current assets			
Plant and equipment		773	638
Intangible assets	4	97,844	98,824
Right of use assets		2,546	2,630
Total non-current assets		101,163	102,092
Total assets		121,036	128,354
Liabilities			
Current liabilities			
Trade and other payables		3,781	5,227
Employee provisions		2,328	2,516
Lease liabilities		696	616
Income tax payable		518	488
Unearned revenue		9,122	12,906
Contingent consideration	5	2,663	2,638
Total current liabilities		19,108	24,391
Non-current liabilities			
Employee provisions		83	141
Deferred tax liabilities		7,999	7,999
Unearned revenue		943	-
Lease liabilities		1,788	1,868
Total non-current liabilities		10,813	10,008
Total liabilities		29,921	34,399
Net assets		91,115	93,955
Equity			
Issued capital	6	110,511	110,511
Share based payment reserves		687	555
Foreign currency translation reserve		745	875
Accumulated losses		(20,828)	(17,986)
Total equity		91,115	93,955

The notes following the financial statements form part of the financial report.

Statement of changes in equity

CONSOLIDATED	Issued capital	Share capital received in advance	Share based payment reserves	Foreign currency translation reserve	Accumulated losses	Total equity
	\$000	\$000	\$000	\$000	\$000	\$000
Balance as at 1 July 2021	58,569	-	227	-	(13,574)	45,222
Loss for the period	-	-	-	-	(5,950)	(5,950)
Other comprehensive income net of tax	-	-	-	(292)	-	(292)
Total comprehensive income	-	-	-	(292)	(5,950)	(6,242)
<i>Transactions with owners in their capacity as owners:</i>						
Share capital issued	40,651	-	-	-	-	40,651
Share capital received in advance	-	11,576	-	-	-	11,576
Share-based payment expense	-	-	154	-	-	154
Balance at 31 Dec 2021	99,220	11,576	381	(292)	(19,524)	91,361
Balance as at 1 July 2022	110,511	-	555	875	(17,986)	93,955
Loss for the period	-	-	-	-	(2,842)	(2,842)
Other comprehensive income net of tax	-	-	-	(130)	-	(130)
Total comprehensive income	-	-	-	(130)	(2,842)	(2,972)
<i>Transactions with owners in their capacity as owners:</i>						
Share-based payment expense	-	-	132	-	-	132
Balance at 31 Dec 2022	110,511	-	687	745	(20,808)	91,115

The notes following the financial statements form part of the financial report.

Statement of cash flows

CONSOLIDATED	Note	31 Dec 2022 \$000	31 Dec 2021 \$000
Cash flows from operating activities			
Receipts from customers		18,819	16,406
Payments to suppliers and employees		(23,753)	(18,247)
Income tax paid		-	(9)
Interest received		43	13
Finance costs		(64)	(26)
Net cash (outflow) from operating activities		(4,955)	(1,863)
Cash flows from investing activities			
Payments for plant and equipment		(293)	(162)
Payment for purchase of business, net of cash acquired	3	-	(56,463)
Net cash (used) for investing activities		(293)	(56,625)
Cash flows from financing activities			
Proceeds from issues of equity securities		-	43,425
Proceeds received in advance of securities being issued		-	11,575
Transaction costs related to issues of equity securities		-	(2,223)
Repayment of principal on lease liabilities		(303)	(419)
Net cash (outflows)/inflows from financing activities		(303)	52,358
Net (decrease) in cash and cash equivalents		(5,551)	(6,130)
Effects of exchange rate changes on cash and cash equivalents		80	41
Cash and cash equivalents at the beginning of the period		17,339	25,027
Cash and cash equivalents at the end of the period		11,868	18,938

The notes following the financial statements form part of the financial report.

Notes to the financial statements

1. General information

Alcidion Group Limited (“Alcidion” or the “Group” or the “Company”) is a limited company incorporated in Australia. The core of Alcidion’s business model is to create intellectual property in the form of Clinical Information System software developed to improve the quality of care for all patients and improve the productivity of clinicians and care teams.

The Company’s software is bundled with other technologies and services to create complete clinical and business solutions for healthcare providers. Alcidion builds, sells, delivers, hosts and supports solutions for health care provider organisations in Australia, New Zealand and the United Kingdom.

2. Statement of significant accounting policies

These consolidated financial statements are general purpose interim financial statements which have been prepared in accordance with the Corporations Act 2001, and Australian Accounting Standard AASB 134: Interim Financial Reporting. Compliance with AASB 134 ensures compliance with International Financial Reporting Standard IAS 34 ‘Interim Financial Reporting’

This interim financial report is intended to provide users with an update on the latest annual financial statements of the Group. As such, it does not contain information that represents relatively insignificant changes occurring during the half-year within the Group. It is therefore recommended that this financial report be read in conjunction with the annual financial statements of the Group for the year ended 30 June 2022, together with any public announcements made during the half year.

The half-year financial statements were authorised for issue by the directors on 24 February 2023.

2.1 Basis of preparation

The financial statements comprise the consolidated financial statements of the Group which comprises the Company and its legal subsidiaries. For the purposes of preparing the consolidated financial statements, the Group is a for-profit entity. Except for the changes disclosed at Note 2.2 below, the same accounting policies and methods of computation have been followed in this interim financial report as were applied in the most recent financial statements.

The condensed interim financial consolidated financial statements of the Group are for the six months ended 31 December 2022 and are presented in Australian Dollars (\$AUD), which is the functional currency of the Parent Company.

2.2 New or amended accounting standard and interpretations adopted

The Group has adopted all new or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board (‘AASB’) that are mandatory for the current reporting period. There has been no impact from this adoption.

Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been adopted early.

3. Depreciation and amortisation

	31 Dec 2022 \$000	31 Dec 2021 \$000
Depreciation of plant and equipment	160	88
Depreciation of right of use assets	402	446
Amortisation of intangible assets	980	-
Total Depreciation and amortisation	1,542	534

4. Intangible assets

	Goodwill \$000	Intellectual property \$000	Customer contracts \$000	Acquired Software \$000	Patents & Trademarks \$000	Total \$000
Cost						
At 1 July 2021	25,460	1,714	-	-	341	27,515
Additions – Silverlink	43,109	-	12,985	14,679	-	70,773
Additions – Extramed	(2,520)	-	2,610	1,720	-	1,810
Re-allocation	1,714	(1,714)	-	-	-	-
At 30 June 2022	67,763	-	15,595	16,399	341	100,098
At 1 July 2022	67,763	-	15,595	16,399	341	100,098
Additions	-	-	-	-	-	-
At 31 December 2022	67,763	-	15,595	16,399	341	100,098
Accumulated amortisation						
At 1 July 2021	-	-	-	-	26	26
Amortisation expense	-	-	859	378	11	1,248
At 30 June 2022	-	-	859	378	37	1,274
At 1 July 2022	-	-	859	378	37	1,274
Reallocation	-	-	(481)	481	-	-
Amortisation expense	-	-	280	695	5	980
At 31 December 2022	-	-	658	1,554	42	2,254
Carrying value						
At 30 June 2022	67,763	-	14,736	16,021	304	98,824
At 31 December 2022	67,763	-	14,937	14,845	299	97,844

5. Contingent Consideration

	31 Dec 2022 \$000	30 June 2022 \$000
Opening balance: Contingent consideration - current liability	2,638	-
Origination of contingent consideration	-	2,823
Impact of foreign exchange differences recorded in OCI	25	(185)
Closing balance: Contingent consideration - current liability	2,663	2,638

Contingent consideration relates to the acquisition of Silverlink Software PCS Limited. Payment of the contingent consideration is subject to the successful renewal of selected customer contracts prior to 31 March 2024. Should the contracts not be renewed by 31 March 2024 no consideration would be payable.

The contingent consideration was split into two equal tranches. The first tranche was settled in the year ended 30 June 2022. The second tranche is subject to the successful renewal of selected customer contracts, these renewals are expected to take place on or before 31 March 2023 (but no later than 31 March 2024) and as such the second tranche of the contingent consideration is accounted for as a current liability.

The basis of the contingent payment is estimated fair value and determined by taking into account the high probability that Alcidion will renew the selected customer contracts that trigger the full payment of the contingent consideration.

This liability is considered a Level 3 financial liability that is remeasured each reporting date based on probability factors. Any changes to the fair value measurement of the contingent consideration will be recognised in Profit or Loss.

6. Issued capital

Consolidated	31 Dec 2022	30 June 2022
	\$000	\$000
1,268,069,053 fully paid ordinary shares (30 June 2022: 1,268,069,053)	110,511	110,511

	6 Months to 31 December 2022		12 months to 30 June 2022	
	No.	\$000	No.	\$000
Opening balance	1,268,069,053	110,511	1,048,069,052	58,569
Shares issued during the period	-	-	220,000,001	51,942
Closing balance	1,268,069,053	110,511	1,268,069,053	110,511

Fully paid ordinary shares carry one vote per share and carry the right to dividends.

7. Dividends

There were no dividends paid or proposed during the period.

8. Loss per share

Earnings (loss) per share	31 Dec 2022	31 Dec 2021
	Cents	Cents
Basic and diluted earnings (loss) per share	(0.22)	(0.56)

(a) Earnings used in calculating basic and diluted earnings per share

	31 Dec 2022	31 Dec 2021
	\$000	\$000
(Loss) attributable to ordinary shareholders of the Group used in calculating basic and diluted earnings (loss) per share	(2,842)	(5,950)

(b) Weighted average number of shares used as denominator to calculate basic and diluted earnings per share

	December 2022	December 2021
	No.	No.
Weighted average number of ordinary shares used in calculating basic earnings per share	1,268,069,053	1,064,117,153
diluted earnings per share	1,288,403,808	1,073,645,738

9. Commitments

As at 31 December 2022 the Group has no commitments (30 June 2022: nil)

10. Contingencies

In the opinion of the Directors, the Group did not have any contingent liabilities or contingent assets as at 31 December 2022 (30 June 2022: nil).

11. Segment reporting

The Group operates in the healthcare industry in Australia, New Zealand and the UK. For management purposes, the Group is organised into one main operating segment which involves the provision of healthcare software solutions in all these territories. All the Group's activities are inter-related and financial information is reported to the Board (Chief Operating Decision Maker) as a single segment. All significant operating decisions are based upon analysis of the Group as one segment. The financial results of this segment are therefore equivalent to the financial statements of the Group.

Basis of accounting for purposes of reporting by operating segments

Accounting policies adopted

Unless stated otherwise, all amounts reported to the Board of Directors, being the chief operating decision makers with respect to operating segments, are determined in accordance with accounting policies that are consistent with those adopted in the annual financial statements of the Group.

Intersegment transactions

There were no intersegment sales during the period.

Segment information

Group Performance - No separate Group performance has been presented in this report as the Board receives only a consolidated Group performance report which is the equivalent to the statement of Profit or Loss and Other Comprehensive Income of the Group as a whole.

Group assets and liabilities - No separate Group asset and liabilities have been presented in this report as the Board only receives a consolidated asset and liabilities report which is the equivalent to the statement of financial position of the Group as a whole.

Revenue by geographical region	31 Dec 2022		31 Dec 2021	
	\$000	%	\$000	%
Australia / New Zealand	10,236	54%	8,549	66%
United Kingdom	8,748	46%	4,312	34%
Total revenue	18,984		12,861	

Timing of revenue recognition	31 Dec 2022			31 Dec 2021		
	\$000			\$000		
	Goods transferred at a point in time	Service transferred over time	Total	Goods transferred at a point in time	Service transferred over time	Total
Australia / New Zealand	6,271	3,965	10,236	5,740	2,809	8,549
United Kingdom	7,585	1,163	8,748	3,025	1,287	4,312
Total revenue	13,856	5,128	18,984	8,765	4,096	12,861

Major customers

During the period the group had one customer that individually accounts for more than 10% of revenue:

- Leidos Australia \$3,987K (21.0%) (Dec 21: \$1,975K (15.4%))

12. Events after the end of the interim period

No matter or circumstances have arisen since the end of the half-year reporting period which significantly affect the operations of the Group, the results of those operations or the state of affairs of the Group in future years.

Directors' declaration

The directors declare that:

- a) in the directors' opinion, there are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable; and
- b) in the directors' opinion, the attached financial statements and notes thereto are in accordance with the *Corporations Act 2001*, including compliance with accounting standards and giving a true and fair view of the financial position and performance of the Group for the half year ended 31 December 2022.

Signed in accordance with a resolution of the directors made pursuant to s.303(5) of the *Corporations Act 2001*.

On behalf of the Directors



Rebecca Wilson
Non-Executive Chair
Melbourne, 24 February 2023

Independent Auditor's Review Report



Alcidion Group Limited

Independent auditor's review report

Report on the Review of the Half-Year Financial Report

Conclusion

We have reviewed the accompanying half-year financial report of Alcidion Group Limited (the Company) and the entities it controlled at the half-year's end or from time to time during the half year (the consolidated group), which comprises the consolidated statement of financial position as at 31 December 2022, the consolidated statement of profit or loss and other comprehensive income, consolidated statement of changes in equity and consolidated statement of cash flows for the half-year ended on that date, a summary of significant accounting policies and other explanatory information, and the directors' declaration.

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the half-year financial report of Alcidion Group Limited is not in accordance with the *Corporations Act 2001* including:

- a. giving a true and fair view of the consolidated entity's financial position as at 31 December 2022 and of its performance for the half year ended on that date; and
- b. complying with Australian Accounting Standard 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

Basis for Conclusion

We conducted our review in accordance with ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity*. Our responsibilities are further described in the *Auditor's Responsibilities for the Review of the Financial Report* section of our report. We are independent of the Company in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to our audit of the annual financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

Responsibility of Directors for the Financial Report

The directors of the Alcidion Group Limited are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the half-year financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

Independent Auditor's Review Report

Auditor's Responsibilities for the Review of the Financial Report

Our responsibility is to express a conclusion on the half-year financial report based on our review. ASRE 2410 requires us to conclude whether we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with the *Corporations Act 2001* including giving a true and fair view of the Company's financial position as at 31 December 2022 and its performance for the half-year ended on that date, and complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



William Buck (SA)
ABN: 38 280 203 274



G.W. Martinella
Partner

Dated this 24th day of February, 2023.

Corporate Directory

Current Directors (Alcidion Group Limited)

Name	Position	Date of Appointment
Ms Rebecca Wilson	Non-Executive Chair	01/08/2017
Ms Kate Quirke	Managing Director	03/07/2018
Mr Simon Chamberlain	Non-Executive Director	01/07/2019
Ms Victoria Weekes	Non-Executive Director	01/09/2021
Mr Daniel Sharp	Non-Executive Director	01/09/2021
Ms Melanie Leydin	Company Secretary	04/03/2019

Registered office

Level 4
100 Albert Road
South Melbourne VIC 3205

Principal place of business

Level 10
9 Yarra Street
South Yarra VIC 3141
☎ 1800 767 873

Website

www.alcidion.com

Registers of securities

Computershare Investor Services Pty Ltd
Level 5, 115 Grenfell Street,
Adelaide SA 5000

Auditors

William Buck
Level 6, 211 Victoria Square
Adelaide SA 5000

☎ +61 8 8409 4333

☎ +61 8 8409 4499

Stock Exchange

Australian Securities Exchange Limited
Exchange Centre
20 Bridge Street
Sydney, NSW 2000

ASX Code: **ALC**

DSG

Castle Chambers, 43 Castle Street
Liverpool L2 9TL
England UK

☎ +44 151 294 5400

Tax Accountants

BDO
Level 11, 1 Margaret St
Sydney, NSW, 2000

☎ +61 2 9251 4100

Bankers

Westpac Banking Corporation
Level 30, 275 Kent Street
Sydney, NSW, 2000



ABOUT ALCIDION

Alcidion Group Limited (Alcidion) has a simple purpose, that is, to transform healthcare with proactive, smart, intuitive technology solutions that improve the efficiency and quality of patient care in healthcare organisations, worldwide.

Alcidion offers a complementary set of software products and technical services that create a unique offering in the global healthcare market. Based on the flagship product, Miya Precision, the solutions aggregate meaningful information to centralised dashboards, support interoperability, facilitate communication and task management in clinical and operational settings and deliver Clinical Decision Support at the point of care; all in support of Alcidion's mission to improve patient outcomes.

Since listing on the ASX in 2011, Alcidion has acquired multiple healthcare IT companies and expanded its foothold in the UK, Australia, and New Zealand to now service over 400 hospitals and 87 healthcare organisations, with further geographical expansion planned.

With over 20 years of healthcare experience, Alcidion brings together the very best in technology and market knowledge to deliver solutions that make healthcare better for everyone.

© Alcidion Group Limited 2023. Alcidion, Miya Precision, Patientrack and Smartpage are registered trademarks. All other brands and product names and trademarks are the registered property of their respective companies.

www.alcidion.com
investor@alcidion.com

Head Office

Level 10, 9 Yarra Street
SOUTH YARRA VIC 3141
AUSTRALIA
P 1800 767 873